anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: There is little information about predictors of physical therapy (PT) use among injured workers with back pain. The primary objective of this study is to investigate the associations between PT use and baseline factors not routinely captured in workers' compensation (WC) data.
METHODS: We conducted a secondary analysis using the Washington State Workers' Compensation Disability Risk Identification Study Cohort, which combines self-reported surveys with claims data from the Washington State Department of Labor and Industries State Fund. Workers with an accepted or provisional WC claim for back injury between June 2002 and April 2004 were eligible. Baseline factors for PT use were selected from six domains (socio-demographic, pain and function, psychosocial, clinical, health behaviors, and employment-related). The outcome was a binary measure for PT use within 1 year of injury. Bivariate and multivariable logistic regression models were conducted to evaluate the associations between PT use and baseline factors.
RESULTS: Among the 1370 eligible study participants, we identified 673 (49%) who received at least one PT service. Baseline factors from five of the six domains (all but health behaviors) were associated with PT use, including gender, income, pain and function measures, injury severity rating, catastrophizing, recovery expectations, fear avoidance, mental health score, body mass index, first provider seen for injury, previous injury, and several work-related factors.
CONCLUSION: We identify baseline factors that are associated with PT use, which may be useful in addressing disparities in access to care for injured workers with back pain in a WC system.
Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings..
Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition of high dispersion with high shield against ultraviolet rays and high stability by using fine particles of specifically treated titanium oxide, zinc oxide and clay mineral. SOLUTION: This cosmetic composition contains three different kinds of base materials, in other words, fine particles of titanium oxide, zinc oxide and clay mineral which are surface-treated with at least one of silicone oils, for example, methyl hydrogen polysiloxane or the like. The weight ratio of the silicone-treated fine particles of titanium oxide, zinc oxide and clay mineral is (10-80)/(80-10)/(10-30), particularly (45-65)/(30-10)/(10-20). One or more among these three components preferably form secondary coagulation particles. In addition, at least one among the three components are crushed or disintegrated and simultaneously silicone is adsorbed or bonded to the crushed or disintegrated products. This cosmetic composition is used in an amount of 5-20wt.% in a cosmetic.
Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
The pathogenesis-related 1 gene of watermelon responds to the infection of ZYMV and contributes to the resistance of its host. Zucchini yellow mosaic virus (ZYMV; family Potyviridae) is a single-stranded positive-sense RNA virus that is a serious threat to cucurbits. Previously, we observed a hypersensitivity response (HR) in the systemic leaves of the 938-16-B watermelon line infected with ZYMV, distinct from the typical HR at infected sites. In this study, we confirmed that ZYMV accumulation in 938-16-B was significantly lower than in the susceptible line H1. Upon inoculation, the entry of ZYMV-eGFP into mesophyll cells is restricted into necrotic spots in leaves, indicating that resistance to ZYMV in 938-16-B is linked to the HR. Further, grafting experiments between 938-16-B and susceptible varieties were performed, and revealed an HR induction in susceptible varieties, suggesting the transfer of resistance signal(s) from 938-16-B to susceptible varieties. Through RNA-sequencing and proteomics analyses of the H1 scions on 938-16-B rootstock, a pathogenesis-related 1 (ClPR1) gene was identified. Specifically, ClPR1 expression is unique to ZYMV-infected 938-16-B. Repression of the expression of ClPR1 prevents an HR in 938-16-B. Conversely, overexpression of ClPR1 in susceptible varieties significantly reduces ZYMV accumulation, but an HR was not induced in susceptible line. Besides the virus, jasmonic acid (JA) can also trigger an HR in 938-16-B. Intriguingly, the expression of ClPR1 (Cla97C02G034020) is induced in both of 938-16-B and H1 by MeJA, rather than salicylic acid. These results suggest that HR is associated with the expression of ClPR1 and contributes to resistance to ZYMV in 938-16-B.
BACKGROUND & AIMS: Sarcopenia, characterized by loss of muscle mass and decreased muscle strength, significantly affects adults but also influences pediatric health. However, definitions for low muscle mass, decreased strength, and sarcopenia in children are less established, impacting interventions for improving health outcomes. The objective of this scoping review is synthesize the existing literature on the diagnostic criteria, prevalence and clinical outcomes of sarcopenia.
METHODS: A scoping review, following the PRISMA extension for scoping reviews, examined pediatric sarcopenia literature until June 2023. The literature search was performed using MEDLINE and the Cochrane Central Register of Controlled Trials with the last search conducted on June 30, 2023. Criteria included studies on aged 0-20 years, covering healthy subjects, acutely ill patients, and chronic disease cases excluding specific conditions like neuromuscular diseases or prematurity.
RESULTS: Initial search found 503 studies, finally, we included 56 studies. Most studies diagnosed sarcopenia using skeletal muscle mass indicators like total psoas muscle area from Computed Tomography or Magnetic Resonance Imaging. Around half of the longitudinal studies highlighted sarcopenia as a risk factor for various clinical outcomes, predominantly in hospitalized patients. However, cutoff values for sarcopenia indicators lacked consistency, with studies employing diverse percentile-based measurements or z-scores.
CONCLUSION: Pediatric sarcopenia diagnosis primarily relies on skeletal muscle mass, with identified links to future clinical outcomes in specific conditions. The lack of standardized cutoffs for sarcopenia indicators underscores the necessity for age, gender, and race-specific cutoff values derived from studies establishing reference values for muscle mass and strength across diverse pediatric populations.
Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
PURPOSE:To obtain the titled pharmaceutical containing a tumor necrosis factor (TNF). CONSTITUTION:A tumor vascular permeability accelerator obtained by containing a tumor necrosis factor (TNF), e.g. a recombinant type human tumor necrosis factor, produced in Escherichia coli by genetic engineering and having 155 amino acid residues, etc.; cellulicidal effect providing 50% survival rate after incubating 10,000 L-M cells derived from mice at 37 deg.C for 48hr is taken as 1 unit (U) for activity units of the TNF, as an active ingredient. The content of the TNF is 10,000-10,000,000U/day administered once or in divided portions. Distribution of a carcinostatic agent into cancerous tissues can be enhanced by administering this accelerator about 1hr before administering the carcinostatic agent.
The hospital records of TBR HAT patients will be examined for date of symptom onset (if available) and hospital admission, race, sex, age, geographic area of origin, parasites, concomitant medications and illnesses, co-infections, and disease stage. Patients are normally screened for HAT and other tropical diseases using standard parasitological World Health Organization (WHO) criteria. Briefly, blood is obtained from the patients and checked for the presence of trypanosomes using direct wet smear and capillary centrifugation technique methods. Disease stage determination is by examination of CSF using the WHO criteria which classify patients with the presence of trypanosomes in the CSF and/or a WBC count \>5 cells/mm3 as Stage 2 TBR HAT. Stage 2 patients would be disqualified from inclusion in the study.
Participants will be monitored through existing wait-list practices. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
PURPOSE:To obtain a therapeutic agent for bone diseases, containing a liblomycin as the active component and having an excellent osteogenesis promotion effect and an excellent bone resorption inhibitory effect. CONSTITUTION:A compound represented by the formula (R1 and R2 are H or an alkyl) or its salt is contained as the active component. The compound of the formula has a remarkable differentiation and calcification promotion effect on osteoblast and a remarkable differentiation effect and a maturation inhibitory effect on osteoclast. This medicine is effective for therapy of endogenous bone diseases such as reduction of bone weight or exogenous bone diseases such as physical fracture or reduction of therapeutic period and useful for therapy of, e.g. osteoporosis, hypercalcemia, bone Paget's disease, traumatic fracture, fatigue fracture, osteomalacia, nutritional disorder, malignant tumor and weakened osseous tissue or fracture caused by other diseases and for reduction of therapeutic period. This medicine is orally or parenterally administrated in an amount of 10mg to 10g/day per an adult.
Acquired choanal atresia is a rare complication of pharyngeal surgical interventions. Here, we report the case of a 72-year-old woman who was treated in our institution for acquired choanal atresia after failed previous treatments. We have excised the obstructing fibrotic scar tissue and then reconstructed the area using a mucosal local flap and free radial forearm flap transfer. Choanal stenosis caused by abnormal granulation was identified in the months after surgery; however, this was treated with endoscopic dilatation and steroid injections in the outpatient setting. No restenosis was identified 1 year after the operation. Postoperative evaluation of speech was satisfactory. Free flap transfer could be an option for refractory choanal atresia, and endoscopic dilatation with local steroid injections may be an effective method to treat postoperative restenosis.
Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
This multi-site, open-label, Phase 2, lead-in study assesses the safety and efficacy of MDMA-assisted therapy in participants diagnosed with at least severe posttraumatic stress disorder (PTSD). Therapy teams that have been identified and trained to work on the sponsor's planned Phase 3 studies will treat at least one open-label participant in this study.

This study will compare the effects of three open-label manualized Experimental Sessions of psychotherapy assisted by flexible doses of MDMA. Initial doses per Experimental Session include 80 mg or 120 mg of MDMA compounded with lactose, followed 1.5 to 2 hours later by a supplemental half-dose (40 mg or 60 mg). Total amounts of MDMA to be administered per Experimental Session range from 80 mg to 180 mg. This \~12-week Treatment Period is preceded by three Preparatory Sessions. During the Treatment Period, each Experimental Session is followed by three Integrative Sessions of non-drug psychotherapy. The Primary Outcome measure is the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline to Primary Endpoint (Visit 19).
Master formula and obtaining procedure, based on vaseline, lanolin, beeswax, olive oil or their mixtures, includes lasallia pustulata and flowering tops of thymus vulgaris, lavandula officinalis, honey, and propolis tincture, optionally cannabis sativa leaves and florid sumidad of calendula officinalis. For every 1 kg of base, it contains: - 50 grams of lasallia pustulata. - 50 grams of thymus vulgaris. - 50 grams of lavandula officinalis. - 250 grams of beeswax. -40 grams of pure honey. - 6.5 grams of propolis tincture. Optionally, up to 150 grams of lasallia pustulata, leaves of cannabis sativa, and calendula officinalis. To obtain it, the base is heated, flowering tops of thymus vulgaris, lavandula officinalis, calendula officinalis, lasallia pustulata, cannabis sativa leaves, dry and powdered are introduced. It is maintained at 65º -80º five hours, the wax, honey, propolis tincture is introduced and filtered. (Machine-translation by Google Translate, not legally binding)
PROBLEM TO BE SOLVED: To provide HER-2 peptides.SOLUTION: This invention relates to compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein. Such compositions include epitopes of the HER-2 proteins. In some embodiments, the HER-2 B epitopes are immunogenic. The present invention additionally provides compositions that include one or more chimeric peptides, and the chimeric peptides include the HER-2 B epitopes. Additionally, compositions having one or more multivalent peptides are provided. These multivalent peptides include two or more HER-2 B epitopes.
The present invention relates to a composition for improving a skin condition and including omega-7 derived from refined fish oil and red ginsengs. The composition according to the present invention includes an omega-7 and red ginseng composite material as an active ingredient, and thus exhibits an excellent skin improving effect. The composition for improving a skin condition according to the present invention comprises, at optimized concentrations, omega-7 derived from refined fish oil, and red ginsengs containing saponine, polysaccharides and the like as active ingredients. Thus, on the basis of high stability, the effects of improving skin moisturizing, improving skin protection barriers, and inhibiting cell damage caused by oxidative stress are ensured. Accordingly, a comprehensive skin condition improvement effect is exhibited with respect to damage to skin caused by external stimuli such as fine dust. Also, antioxidant, anti-inflammatory, skin elasticity, and anti-wrinkle effects are ensured, and an excellent skin aging inhibitory effect is exhibited. The composition according to the present invention comprehensively exhibits a fundamental skin condition improvement effect, and thus is expected to be variously utilized for food, health functional food, food additives, cosmetics, and the like.
ABSTRACT OF THE DISCLOSURE The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the Vii, VI, and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof.  Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP. Date Recue/Date Received 2020-04-30
Spheroids containing active materials other than tiagabine,  their preparation, and their use in the preparation of pharmaceuticals. The spheroids have a diameter of 0.25 - 3 mm, preferably 0.5 - 1 mm and comprise a core and/or a coating layer around the core containing a thermoplastic excipient (II) which has a pasty to semi-solid consistency at 20 deg C and a melting temperature between 25 and 100 deg C.  This is coated with a supple and deformable film of polymeric material (III) especially one having a glass transition temperature below about 30 deg C, especially below 20 deg C, this film giving protection, masking the flavor, and allowing modified and controlled liberation of the active material (I).  The thermoplastic excipient (II) is preferably a partially hydrogenated oil, carnauba wax, paraffin wax, silicone wax, fatty acids and alcohols with 12 - 18 C atoms, solid semi-synthetic glycerides, glycerol esters, polyoxyethylene glycols, glycosylated polyoxyethylene glycerides, and their mixtures.  The polymeric material (III) is preferably mixed with a plasticizer especially triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, triacetin, diethyl phthalate, polyethylene glycols, polysorbates, mono- and di-acetylated glycerides, and their mixtures.  (III) and its plasticizer preferably have a percentage elongation above 50%.  The spheroids may also have a water-dispersible external layer, such as of an acrylic, vinyl or cellulosic polymer, to ensure cohesion of the spheroids when they are compressed to form tablets and to ensure that tablets so made disintegrate in water.
Glaucoma is the leading cause of irreversible blindness worldwide. The most important test to detect progression is visual field testing. Visual field testing is the reference standard to measure visual function in glaucoma. It is called called standard automated perimetry (SAP). However, this test is very subjective, often unreliable, and variable. One of the main causes of unreliable tests is the lack of attentiveness or concentration during the test. Previous studies have shown that listening to Mozart or taking vitamin B12 can improve the reliability of this test. Recent studies have suggested that over-the-counter medications such as nicotinamide (vitamin B3) and pyruvate can also improve the performance during this test. This can ultimately reduce costs due to repeated testing and increase doctor's certainty when analyzing the results of this test.
According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for the included participants, who all have the pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating nuts intake of less than 2.5 oz per week.
The present invention relates to a new vector, the myelinosome, for intracellular delivery of molecules of interest, such as nucleic acids, proteins or chemical molecules. The Inventors for example showed that myelinosomes loaded with a protein or nucleic acid of interest are efficiently delivered into target cells. Besides, treatment of cells with myelinosomes carrying a functional protein (for example wild-type CFTR protein) rescued the phenotype of diseased cells carrying a nonfunctional protein (for example human cystic fibrosis bronchoepithelial cells carrying CFTR mutation). The present invention thus particularly relates to the use of myelinosomes for delivering at least one molecule of interest in vitro or in vivo, for example for the prevention, treatment and/or diagnostic of a disease. The present invention also relates to a method for producing myelinosomes, compositions suitable for in vitro use comprising said myelinosomes and pharmaceutical compositions comprising said myelinosomes. Figure: none
In Study MRS-TU-2019EXT, Testosterone Undecanoate Capsules increased 24-hour average systolic blood pressure (SBP) measured by ambulatory blood pressure monitoring (ABPM) by 1.7 mmHg from baseline after 4 months of treatment and 1.8 mmHg from baseline after 6 months of treatment [see Adverse Reactions (6.1)] . Three percent of Testosterone Undecanoate Capsules treated patients were started on antihypertensive medications during the 6-month trial.

A history of antihypertensive treatment and diabetes mellitus at baseline were significant factors related to ambulatory SBP increases [see Adverse Reactions (6.1)].

Blood pressure (BP) increases can increase the risk of major adverse cardiovascular events (MACE), with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease. In some patients, the increase in BP with Testosterone Undecanoate Capsules may be too small to detect but can still increase the risk for MACE.

Before initiating Testosterone Undecanoate Capsules, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. Check BP periodically after initiating Testosterone Undecanoate Capsules or increasing the dose and thereafter. Treat new-onset hypertension or exacerbations of pre-existing hypertension. Re-evaluate whether the benefits of continued treatment with Testosterone Undecanoate Capsules outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease.
Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.